A time-driven, activity-based costing methodology for determining the costs of red blood cell transfusion in patients with beta thalassaemia major.


Journal

Transfusion medicine (Oxford, England)
ISSN: 1365-3148
Titre abrégé: Transfus Med
Pays: England
ID NLM: 9301182

Informations de publication

Date de publication:
Feb 2019
Historique:
received: 25 10 2017
revised: 22 02 2018
accepted: 02 03 2018
pubmed: 11 4 2018
medline: 25 4 2019
entrez: 12 4 2018
Statut: ppublish

Résumé

To describe the methodology to estimate the total cost of administration of a single unit of red blood cells (RBC) in adults with beta thalassaemia major in an Australian specialist haemoglobinopathy centre. Beta thalassaemia major is a genetic disorder of haemoglobin associated with multiple end-organ complications and typically requiring lifelong RBC transfusion therapy. New therapeutic agents are becoming available based on advances in understanding of the disorder and its consequences. Assessment of the true total cost of transfusion, incorporating both product and activity costs, is required in order to evaluate the benefits and costs of these new therapies. We describe the bottom-up, time-driven, activity-based costing methodology used to develop process maps to provide a step-by-step outline of the entire transfusion pathway. Detailed flowcharts for each process are described. Direct observations and timing of the process maps document all activities, resources, staff, equipment and consumables in detail. The analysis will include costs associated with performing these processes, including resources and consumables. Sensitivity analyses will be performed to determine the impact of different staffing levels, timings and probabilities associated with performing different tasks. Thirty-one process maps have been developed, with over 600 individual activities requiring multiple timings. These will be used for future detailed cost analyses. Detailed process maps using bottom-up, time-driven, activity-based costing for determining the cost of RBC transfusion in thalassaemia major have been developed. These could be adapted for wider use to understand and compare the costs and complexities of transfusion in other settings.

Sections du résumé

OBJECTIVES OBJECTIVE
To describe the methodology to estimate the total cost of administration of a single unit of red blood cells (RBC) in adults with beta thalassaemia major in an Australian specialist haemoglobinopathy centre.
BACKGROUND BACKGROUND
Beta thalassaemia major is a genetic disorder of haemoglobin associated with multiple end-organ complications and typically requiring lifelong RBC transfusion therapy. New therapeutic agents are becoming available based on advances in understanding of the disorder and its consequences. Assessment of the true total cost of transfusion, incorporating both product and activity costs, is required in order to evaluate the benefits and costs of these new therapies.
METHODS METHODS
We describe the bottom-up, time-driven, activity-based costing methodology used to develop process maps to provide a step-by-step outline of the entire transfusion pathway. Detailed flowcharts for each process are described. Direct observations and timing of the process maps document all activities, resources, staff, equipment and consumables in detail. The analysis will include costs associated with performing these processes, including resources and consumables. Sensitivity analyses will be performed to determine the impact of different staffing levels, timings and probabilities associated with performing different tasks.
RESULTS RESULTS
Thirty-one process maps have been developed, with over 600 individual activities requiring multiple timings. These will be used for future detailed cost analyses.
CONCLUSIONS CONCLUSIONS
Detailed process maps using bottom-up, time-driven, activity-based costing for determining the cost of RBC transfusion in thalassaemia major have been developed. These could be adapted for wider use to understand and compare the costs and complexities of transfusion in other settings.

Identifiants

pubmed: 29637650
doi: 10.1111/tme.12523
doi:

Types de publication

Clinical Trial Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

33-40

Subventions

Organisme : Celgene Pty Ltd (Celgene Australia)

Informations de copyright

© 2018 British Blood Transfusion Society.

Auteurs

K E Burns (KE)

Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.

H E Haysom (HE)

Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.

A M Higgins (AM)

Centre for Research Excellence in Patient Blood Management in Critical Illness and Trauma, Monash University, Melbourne, Victoria, Australia.

N Waters (N)

Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.

R Tahiri (R)

Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.

K Rushford (K)

Monash Medical Centre, Monash Health, Melbourne, Victoria, Australia.

T Dunstan (T)

Monash Medical Centre, Monash Health, Melbourne, Victoria, Australia.

K Saxby (K)

Centre for Health Economics, Monash University, Melbourne, Victoria, Australia.

Z Kaplan (Z)

Monash Medical Centre, Monash Health, Melbourne, Victoria, Australia.

S Chunilal (S)

Monash Medical Centre, Monash Health, Melbourne, Victoria, Australia.

Z K McQuilten (ZK)

Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Centre for Research Excellence in Patient Blood Management in Critical Illness and Trauma, Monash University, Melbourne, Victoria, Australia.
Monash Medical Centre, Monash Health, Melbourne, Victoria, Australia.

E M Wood (EM)

Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Monash Medical Centre, Monash Health, Melbourne, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH